内脏利什曼病合并噬血细胞性淋巴组织细胞增生症：非流行地区的一例病例报告
Visceral leishmaniasis complicated by hemophagocytic lymphohistiocytosis: A case report from a nonendemic area.
作者信息
Joudeh Anwar I, Elsiddig Awadelkarim Hussein A, Gul Mohammadshah Isam, Elayana Mahmoud Salm, Soliman Dina Sameh, Amer Aliaa, Alsamawi Musaed
机构信息
Department of Internal Medicine, Al-Khor Hospital Hamad Medical Corporation Doha Qatar.
Department of Internal Medicine, Hamad General Hospital Hamad Medical Corporation Doha Qatar.
出版信息
Clin Case Rep. 2023 May 4;11(5):e7309. doi: 10.1002/ccr3.7309. eCollection 2023 May.
KEY CLINICAL MESSAGE
Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many features in common and may coincide in the same patient. Timely diagnosis and management of visceral leishmaniasis could save patients from unnecessary toxic treatment.
ABSTRACT
Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many clinical features in common and may coexist in the same patient. Visceral leishmaniasis should be promptly ruled out in patients coming from endemic areas before starting immunosuppressive therapy for hemophagocytic lymphohistiocytosis. The mainstay treatment, in this case, is anti-leishmania medications preferably liposomal amphotericin-B.
关键临床信息
内脏利什曼病和噬血细胞性淋巴组织细胞增生症有许多共同特征，且可能在同一患者中同时出现。及时诊断和治疗内脏利什曼病可使患者避免不必要的毒性治疗。
摘要
内脏利什曼病和噬血细胞性淋巴组织细胞增生症有许多共同的临床特征，且可能在同一患者中共存。对于来自流行地区的噬血细胞性淋巴组织细胞增生症患者，在开始免疫抑制治疗前应及时排除内脏利什曼病。在这种情况下，主要治疗方法是抗利什曼原虫药物，最好是脂质体两性霉素B。
Zotero 插件